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1. Abstract 
1.1 Purpose 
ZD6474 is a newly developed anti-angiogenic agent that selectively targets two key 
pathways in tumor growth by inhibiting vascular endothelial growth factor receptor 
(VEGFR) and epidermal growth factor receptor (EGFR) tyrosine kinase activity. While 
VEGFR signaling promotes an array of responses in the endothelium including 
endothelial cell proliferation and angiogenesis, EGFR signaling regulates principal 
cellular processes including proliferation, differentiation and apoptosis after cytotoxic 
stress. The purpose of the present study was to evaluate the antitumor efficacy of a 
combination of ZD6474 and radiotherapy in a human tumour xenograft model (Fadu, 
squamous cell carcinoma) and to investigate whether the effects of the treatments are 
related to changes in tumor perfusion, proliferation and apoptosis. 
 
1.2 Methods and Materials 
Tumor-bearing nude mice received either vehicle or ZD6474 (50mg/kg, by mouth, 
once daily for the duration of the experiment), with or without irradiation (5x2 Gy, days 
1-5) (4 treatment-groups: control; ZD6474 alone; radiotherapy (RT) alone; ZD6474 + 
RT). The antitumor efficacy of the different treatment modalities was evaluated by the 
tumor growth delay. For the different treatment-groups the tumor vascularisation was 
evaluated by immunofluorescence analysis of CD34 positive vessel segments (tumor 
vascular density) and the proliferative capacity and apoptotic degree of the tumor tissue 
were analysed by the quantification of Ki67 positive nuclei and Capase-3 positive cell.  
 
1.3 Results 
The tumor growth delay induced by the combined treatment (ZD6474 + RT) was 
greater than that induced by ZD6474 or radiotherapy alone (21.4 ± 2.8 versus 17.7 ± 3.0 
versus 12.5 ± 0.7 days). The application of ZD6474 had significant effects on the tumor 
vasculature resulting in clearly reduced neoangiogenesis. Moreover, the proliferative 
capacity of the tumor tissue was significantly decreased by ZD6474 and apoptosis of 
tumor tissue was significantly increased by ZD6474. 
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1.4 Conclusion 
When irradiation is combined with VEGFR and EGFR blockade, significant 
enhancement of antiangiogenic, antivascular, and antitumor effects were observed. These 
data provide support for clinical trials of biologically targeted and conventional therapies 
in the treatment of cancer.
Introduction 
  
3
2. Introduction 
Ionizing radiation is an effective modality for the treatment of many tumors. It is a 
widely used treatment for cancer, with over half of all cancer patients receiving radiation 
therapy during their course of treatment (Owen et al., 1992; Hendry et al., 1992). 
Although widely used, a need remains to improve the cure rate by radiation therapy alone. 
The most frequent treatment is to combine cytotoxic chemotherapeutic agents with 
irradiation (McGinn et al., 1996; Stratford et al., 1996). The cytotoxicity of 
chemotherapeutic agents, however, is not limited to tumor cells because treatment of 
tumors with these agents can result in significant normal tissue toxicity (Archer et al., 
2003). 
There has been a recent rapid development of a new class of drugs termed 
antiangiogenesis or vascular targeting agents that target the relatively genetically stable 
tumor-associated vasculature (endothelial cells) rather than the genetically unstable tumor 
cell (Kerbel et al., 1991; Lin et al., 1998). The importance of targeting tumor vasculature 
development and function first became apparent in the 1970s through the seminal studies 
of Judah Folkman (Folkman, 1971), who demonstrated that angiogenesis is important for 
the growth and survival of tumor cells. The relationship between angiogenesis and tumor 
growth suggests that both tumor cells and their supporting endothelial cells are potential 
targets for cell killing and should be considered when planning cancer treatment 
(Camphausen et al., 2002). At least four theoretical advantages exist for considering 
tumor endothelial cells as targets for cancer therapy: (a) endothelial cells are more easily 
accessed by antiangiogenic/vascular targeting agents compared with drugs that act on 
tumor cells directly and have to penetrate large bulky masses; (b) antiangiogenic/vascular 
targeting agents may avoid tumor drug resistance mechanisms because they are directly 
cytotoxic to endothelial cells; (c) angiogenesis occurs in very limited circumstances in 
adults (wound healing and ovulation), thus antiangiogenic therapies targeting specific 
receptors on proliferating tumor endothelium potentially are safe and should avoid 
normal tissue toxicities; and (d) because each tumor capillary potentially supplies 
hundreds of tumor cells, targeting of the tumor vasculature should lead to a potentiation 
of the antitumorigenic effect (Scappaticci et al., 2002).  
Investigations of antiangiogenic/vascular targeting agents that have been conducted in 
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preclinical and clinical trials indicate that tumor cures are limited when these agents are 
used as the sole method of treatment (Kerbel et al., 2002). Some recent preclinical studies 
suggest that the combination of radiotherapy and angiogenic blockade enhances the 
therapeutic ratio of ionizing radiation by targeting both tumor cells and tumor vessels 
(Gorski et al., 1998; Mauceri et al., 1996; Mauceri et al., 1998). At present, there is great 
interest in combining antiangiogenic/vascular targeting strategies with conventional 
cytotoxic therapies such as radiotherapy to improve therapeutic gain. The mechanisms by 
which tumor response to radiation is enhanced by these new agents, however, are not 
currently understood. 
 
2.1 Role of angiogenesis in primary tumor growth and metastasis 
A competent and expanding vascular supply is a necessary component of the 
progressive growth of solid tumors because cells in solid tumors, like normal tissue, must 
receive oxygen and other nutrients to survive and grow (Folkman, 1976; Jain, 1988; Jain, 
1999). The connection between oxygen supply and tumor growth was first made in the 
1950s, histological analyses of human and rodent tumors performed by Thomlinson and 
Gray (Thomlinson and Gray, 1955) were the first studies to suggest that regions of viable 
cells exist close to tumor blood vessels and that these walls or cords of viable tumor cells 
correspond in thickness to the distance that oxygen can diffuse (1–2 mm3). The “tumor 
cord” model implied that hypoxic cells exist in a state of oxygen and nutrient starvation 
at the limits of the diffusion range of oxygen, and it was hypothesized that tumor cells 
could proliferate and grow only if they were close to a supply of oxygen from tumor 
stroma. In the 1970s, Folkman (Folkman, 1971) corroborated the earlier findings and 
proposed the importance of tumor vasculature as a viable target for anticancer therapy. 
He reported that a tumor without an adequate blood supply would grow only to a few 
thousand cells in size or around 1–2 mm3, which is the distance that nutrients can enter 
tumor cells by passive diffusion (Folkman, 1971). To increase in size beyond this passive 
diffusion-limited state, the growing tumor mass must acquire new blood vessels. Thus 
angiogenesis is a necessary condition to maintain tumor growth and their subsequent 
metastasis (Fig. 1). 
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Fig. 1: Angiogenesis is a necessary condition for sustained tumor growth (Ferrara et al., 
2004). 
 
2.2 Actions of VEGF in angiogenesis 
A switch to the angiogenic phenotype allows the tumor to expand rapidly. This 
so-called “angiogenic switch” (Hanahan et al., 1996) is regulated by environmental 
factors and by genetic alterations that act to either up-regulate proangiogenic factors (i.e., 
VEGF and basic fibroblast growth factor) (Rak et al., 2001) and transforming growth 
factors (TGF-α and TGF-β) and/or downregulate inhibitors of angiogenesis [i.e., 
angiostatin, endostatin, thrombospondin, and Alpha interferon (IFN-α) (Los et al., 2001)]. 
Tumor angiogenesis is a multistep process of degradation of the extracellular matrix, 
migration and proliferation of endothelial cells from postcapillary venules, and, finally, 
tube formation (Carmeliet et al., 2000). More than 20 endogenous activators and 
inhibitors have been identified in this process (Scappaticci et al., 2002). VEGF is the 
most potent and specific growth factor for endothelial cell activation (Ferrara et al., 2001). 
Evidence for the importance of VEGF-induced angiogenesis in tumor growth was 
demonstrated by use of neutralizing antibodies or a dominant-negative soluble receptor to 
inhibit VEGF action and growth of primary and metastatic experimental tumors (Gorski 
et al., 1999, Asano et al., 1995). VEGF also functions as a powerful antiapoptotic factor 
for endothelial cells in new blood vessels (Benjamin et al., 1999).  
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It has been described that angiogenesis is a multistep process, and VEGF acts at 
several stages to induce the angiogenesis (Fig. 2). (1) VEGF is a potent mitogen for 
vascular endothelial cells, but, with a few exceptions, is not mitogenic for other cell types 
(Ferrara et al., 1997). (2) VEGF mediates the secretion and activation of enzymes 
involved in degrading the extracellular matrix (Unemori et al., 1992; Lamoreaux et al., 
1998). (3) VEGF acts as a survival factor for endothelial cells through the inhibition of 
apoptosis (Alon et al., 1995). This action is mediated through the induction of expression 
of the antiapoptotic proteins: B-cell lymphoma gene-2 and A1 protein, regulation of the 
phosphatidylinositol 3-kinase/Akt pathway, increased phosphorylation of focal adhesion 
kinase, and stimulation of endothelial cell production of prostaglandin I2 (Ferrara et al., 
2001; Zachary et al., 2001). (4) VEGF is essential for the mobilization of bone 
marrow-derived endothelial cell precursors in the promotion of vascularization (Asahara 
et al., 1999; Bertolini et al., 2000). (5) In addition to promoting division of endothelial 
cells, VEGF also has an important role in modulating their migration to sites of 
angiogenesis (Rousseau et al., 2000). Other actions of VEGF include increasing vascular 
permeability (Senger et al., 1983), inhibition of dendritic cell differentiation (Gabrilovich 
et al., 1998), and induction of monocyte migration (Barleon et al., 1996). 
Fig. 2: Multiple functions of VEGF. Abbreviations: EC = endothelial cell; EPC = 
endothelial progenitor cell (Toi et al., 2001). 
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Many factor can induce the expression of VEGF, especially, VEGF is secreted by 
almost all solid tumors (Leung et al., 1989; Bellamy et al., 1999). Factors that lead to 
up-regulation of VEGF expression and secretion include external stresses such as 
ionizing radiation and tumor microenvironment factors such as hypoxia or a decrease in 
pH (Levy et al., 1995; Shweiki et al., 1995; Mukhopadhyay et al., 1995). Moreover, other 
growth factors stimulate VEGF production including insulin-like growth factor I and II, 
epidermal growth factor, and platelet-derived growth factor. Two specific signaling 
pathways are known to mediate the up-regulation of VEGF: (a) the phosphatidylinositol 
3’-kinase/Akt (protein kinase B) signal transduction pathway, which leads to stabilization 
of hypoxia-inducible factor1α (Maxwell et al., 1997; Mazure et al., 1997); (b) The 
mitogen-activated protein kinase (MAPK) pathway, in which activation of extracellular 
signal-regulated kinase increases transcription of the VEGF gene (Fig. 3 summary of the 
VEGF signaling mechanisms). 
 
Fig. 3: Signaling mechanisms involved in VEGF induced tumor angiogenesis. 
Endothelial cell survival and neovascular processes are induced by VEGF/VEGFR2 
signaling via PI3K/Akt signaling axis. VEGF is upregulated by external environmental 
stress (i.e., ionizing radiation) and internal tumor microenvironmental stress (i.e., hypoxia) 
(Jung et al., 1999). 
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Although the growth of solid tumors depends on angiogenesis from generation of a 
vascular network, the amount of newly formed vessels in the stroma of tumor does not 
necessarily lead to increased blood flow (Koukouraki et al., 2001). This inequality exists 
because newly formed microvessels in most solid tumors are abnormal when compared 
with the morphology of the host tissue vasculature (Vaupel et al., 1997). Endothelial cell 
lining of tumor blood vessels differ in many aspects with regard to gene expression from 
those of normal vasculature (St Croix et al., 2000). Due to the lack of adequate vascular 
maturation (Eberhard et al., 2000), vessels often have an incomplete or missing 
endothelial lining, and have interrupted basement membranes that result in an increased 
vascular permeability (Vaupel et al., 1997). Moreover, blood flow is often erratic, with 
even reversal of blood flow within individual vessels (Less et al., 1991). Consequently, 
oxygen availability to the tumor cells shows great variability. Many human tumors 
exhibit hypoxic regions that are heterogeneously distributed within the tumor mass 
(Movsas et al., 2002). Low perfusion rates and hypoxia may then coexist with high 
nonfunctional vascular density, creating hypoxic regions (Eberhard et al., 2000).  In 
these regions of hypoxia, endothelial cells may up-regulate survival factors to maintain 
their integrity and prevent apoptosis (Reinmuth et al., 2001). Thus, so-called “angiogenic 
hot spots” or localized regions of intense angiogenesis may be created and may be 
associated with failure of treatment (Koukourakis et al., 2001). 
 
2.3 Radiation and angiogenesis: a vicious cycle 
Tumor vasculature is abnormal, and the endothelial cell lining of tumor blood vessels 
have different phenotypic properties compared to those of normal vasculature (Eberhard 
et al., 2000). Consequently, increased tumor angiogenesis, as indicated by increased 
microvessel density or by increased VEGF expression, does not necessarily correlate with 
increased blood flow and oxygen availability. This situation, together with the existence 
of heterogeneous hypoxic regions within tumors, makes it difficult to predict how tumor 
angiogenesis will affect response to radiation therapy in a particular tumor. 
Strong evidence exists that cytotoxic therapy alone, such as irradiation, can result in 
intensification of angiogenic processes (Koukourakis et al., 2001). Direct up-regulation 
of VEGF after irradiation of various cancer cell lines has been reported (Gorski et al., 
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1998). This response is part of the overall cellular response to stress and is associated 
with the induction of a variety of transcription factors that can activate transcription of 
cytokines, growth factors, and cell cycle-related genes (Takahashi et al., 1998). The 
products of these genes regulate intracellular signaling pathways through tyrosine kinases, 
MAPKs, stress-activated protein kinases, and ras-associated kinases (Rak et al., 2002). 
These multiple pathways affect tumor cell survival or alter tumor cell proliferation. With 
regard to angiogenesis, radiation exposure can result in activation of the EGFR, which, in 
turn, can activate the MAPK pathway (Bowers et al., 2001). MAPK signaling is linked to 
increased expression of growth factors, such as TGF-αand VEGF. It is possible that 
radiation therapy itself contributes to radioresistance by upregulating and intensifying 
angiogenic pathways. The increased proliferation of tumor cells that is often seen after 
irradiation may be the result of up-regulated angiogenic pathways (Koukourakis et al., 
2001). Although many tumors reoxygenate after irradiation, in tumors that are 
unresponsive to radiation therapy, up-regulated angiogenesis may lead to factors 
contributing to radiation resistance such as increased vascular permeability, decreased 
tumor perfusion, increased oxygen consumption, and up-regulated survival pathways 
(Hansen et al., 2000; Lee et al., 2000). Thus angiogenesis contributes to making radiation 
therapy less effective in some tumors (Kung et al., 2000; Teicher et al., 1994; Vaupel et 
al., 1989). 
 
2.4 Radiation and antiangiogenic interactions 
The existence of tumor microenvironmental factors, such as hypoxia, that can 
up-regulate angiogenic and survival pathways and hence induce resistance to radiation, 
therapy has prompted studies combining antiangiogenic agents with irradiation in an 
effort to overcome this resistance. Teicher et al. (Teicher et al., 1995) were the first to 
show an increased response to single-dose radiotherapy with antiangiogenic agents. Since 
that time a number of preclinical studies have indicated that antiangiogenic agents can 
enhance the tumor response to irradiation (Hess et al., 2001; Huang et al., 2002). The 
differences in tumor response to antiangiogenic agents may come from differences in 
angiogenic growth patterns arising from different angiogenic growth factors such as 
VEGF/VEGFR or EGFR. Radiotherapy plays a role in upregulating the expression of 
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VEGFR and EGFR, both of which are considered key targets for novel anticancer 
therapies. Data from various studies suggest that inhibitors of VEGFR- and 
EGFR-dependent signaling may enhance the cytotoxic effects of radiotherapy (Hess et al., 
2001; Huang et al., 2002). 
 
2.4.1 Radiation and VEGF/VEGFR signaling pathway inhibitors 
Vascular endothelial growth factor has a critical role in pathological angiogenesis 
including sustained neovascularization that is required for all solid tumor growth. The 
signaling response is transmitted to the tyrosine kinase activity of the VEGF family of 
transmembrane receptors. Tyrosine kinase activation is stimulated after VEGF ligand 
binding and receptor dimerization. VEGF is a potent stimulator of endothelial cell 
proliferation, migration, and survival. In addition, VEGF acts as an important endothelial 
survival factor in newly formed vessels and stimulates vessel hyperpermeability, which 
may contribute to the high interstitial pressure commonly observed in solid tumors. The 
critical importance of VEGF in the growth of experimental tumors has been demonstrated 
when stasis or regression was observed after treatment with neutralizing antibodies (Kim 
et al., 1993; Asano et al., 1995; Kanai et al., 1998). Consequently, the development of 
clinically applicable inhibitors of VEGF signaling has been an area of avid research 
(Underiner et al., 2004), these can target either the VEGF protein directly or inhibit the 
activation of the cognate receptors. Of the three major receptors for VEGF family ligands 
[Flt-1 (VEGFR1), KDR (Flk-1; VEGFR2), and Flt-4 (VEGFR3)], VEGFR-2 is 
considered the most important receptor for mediating the angiogenic effects of VEGF. 
Therefore, inhibition of VEGFR-2 mediated tumor angiogenesis has become an 
important therapeutic goal. (Meyer et al., 1999; Zeng et al., 2001; Gille et al., 2001).  
In addition to the effect of VEGF on tumor angiogenesis and growth, VEGF can also 
play an important role in the response of tumors to radiotherapy. This appears to be 
predominantly achieved through the ability of VEGF to enhance endothelial cell survival 
(Gorski et al., 1999; Geng et al., 2001; Hess et al., 2001), recently suggested to be the 
critical factor determining tumor radiation response (Garcia-Barros et al., 2003). These 
observations raise the possibility of combined therapeutic strategies, although there are 
complexities surrounding the application of antiangiogenic agents in a radiotherapy 
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context. In particular, inhibition of VEGF signaling has the potential to impact on tumor 
oxygenation and proliferation kinetics, which could have profound effects on the 
response to irradiation (Griffin et al.,.2002). 
 
2.4.2 Radiation and EGFR signaling pathway inhibitors 
Aberrant EGFR tyrosine kinase activity has been reported in a number of human 
tumors and may contribute to tumor growth and the development of metastases (Harari et 
al., 2004). Radiation exposure not only results in activation of EGFR, but also 
upregulates the downstream MAPK pathway. MAPK signaling in turn is associated with 
increased expression of other growth factors such as TGF-α and VEGF (Park et al., 
2001). 
Several preclinical studies have been conducted with inhibitors of EGFR signaling in 
combination with radiotherapy. Administration of cetuximab (C225), the humanized 
antibody against EGFR, improved the response to radiotherapy in xenograft models of 
non–small-cell lung cancer (Raben et al., 2005) and epidermoid carcinoma (Milas et al., 
2000). Similarly, combining the EGFR tyrosine kinase inhibitor gefitinib with 
radiotherapy produced a cooperative antitumor effect in human colon and lung cancer 
xenografts (Bianco et al., 2002). Furthermore, clonogenic assays revealed a significant 
radiosensitizing action of gefitinib in bladder cancer cell lines (Maddineni et al., 2005). 
The potential mechanisms underlying the enhanced response to radiotherapy in the 
presence of EGFR signaling inhibition remain to be determined. However, possible 
explanations include enhanced tumor cell apoptosis and inhibition of EGFR-dependent 
production of endothelial cell survival factors such as VEGF. Of particular interest are 
the results from a randomized Phase III trial investigating high dose radiotherapy alone or 
in combination with cetuximab (humanized antibody against EGFR) in advanced 
head-and-neck cancer (Bonner et al., 2004). Patients who received combination therapy 
showed a significant prolongation of overall survival compared with those receiving 
radiotherapy alone. These highly promising data will encourage continued clinical 
evaluation of radiotherapy and inhibitors of EGFR as combination therapy. 
 
 
Introduction 
  
12
2.5 ZD6474, an inhibitor of VEGFR and EGFR  
ZD6474 [N-(4–bromo-2–fluorophenyl)–6–methoxy–7-[(1–methylpiperidin–4-yl) 
methoxy] quinazolin-4-amine], is a potent inhibitor of both VEGFR and EGFR tyrosine 
kinase activity (Wedge et al., 2002). ZD6474 inhibits both VEGFR- and EGFR-mediated 
intracellular signaling, and its use in combination with radiotherapy may provide 
significant clinical efficacy (Sandström et al., 2008; Shibuya et al., 2007). Simultaneous 
inhibition of both VEGFR and EGFR signaling may present a novel and exciting 
opportunity to augment the antitumor effects of radiotherapy (Fig. 4). 
 
 
Fig. 4: Mechanism of action of ZD6474, which inhibits both VEGFR and EGFR tyrosine 
kinase activity (Frederick et al., 2006). 
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2.5.1 ZD6474 enhances the therapeutic efficacy of radiotherapy 
Preclinical evidence supporting the combined use of ZD6474 and radiotherapy has 
recently been reported. One study investigated the effects of ZD6474 and radiotherapy on 
human umbilical vein endothelial cell proliferation, as well as on tumor growth in a 
human non–small-cell lung cancer xenograft model (H226 and A549). In vitro, ZD6474 
inhibited human umbilical vein endothelial cell proliferation and induced accumulation of 
cells in G1, inhibited the formation of capillary-like networks, and enhanced the 
radiosensitivity of human umbilical vein endothelial cell in combination with 
radiotherapy. In vivo, the combination of daily oral ZD6474 plus radiotherapy produced 
significantly greater antitumor effects in H226 and A549 tumor xenografts compared 
with single-agent therapy alone (Hoang et al., 2006). 
 
2.5.2 ZD6474 — overcoming resistance to EGFR inhibition  
ZD6474 may also be a useful treatment option in the setting of acquired EGFR 
resistance. Overcoming resistance to EGFR signaling inhibition has been examined in a 
recent study from Ciardiello et al. (Ciardiello et al., 2004). Human colon cancer 
xenografts that had developed resistance to inhibitors of EGFR activity (gefitinib or 
cetuximab) were subsequently exposed to daily dosing of ZD6474. Significant tumor 
growth inhibition for the entire duration of dosing (up to 150 days) was observed with 
administration of ZD6474; in contrast, animals bearing gefitinib- or cetuximab-resistant 
tumors failed to respond when treatment with either EGFR inhibitor was reinitiated after 
a treatment break. Western blot analysis revealed increases in proangiogenic factors in 
the resistant GEO colon tumor cell lines, suggesting a potential mechanism underlying 
the strong antitumor effects of ZD6474 in these experiments. 
 
2.5.3 Pharmacokinetic dosing of ZD6474 in vivo 
Initial preclinical studies with ZD6474 in xenograft models have shown activity 
against a variety of tumor types using doses ranging from 12.5 to 100 mg/kg/d in mouse 
models (Wedge et al., 2002). In these initial studies, most human tumor xenografts 
continued to grow, albeit slowly at doses < 50 mg/kg/d. The most marked antitumor 
effects, including regression, usually required dosing at > 50 mg/kg/d (Gustafson et al., 
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2004). Therefore, preclinical studies may provide more predictive information on 
treatment application of ZD6474. 
The pharmacokinetics of ZD6474 in humans is linear, with a long terminal half-life 
(at least 100 hours) in both Japanese (Minami et al., 2003) and Western populations 
(Holden et al., 2005). At doses of 50–600 mg/d, the plasma levels at steady-state range of 
100–1,100 ng/mL. Steady-state levels are attained only after 20–30 days of daily drug 
dosing owing to the long half-life. The terminal half-life of ZD6474 in mice is 
significantly shorter (30 h) than that seen in humans (Zirrolli et al., 2005). Overall, the 
pharmacokinetics of ZD6474 are consistent with the maintenance of therapeutic levels 
after once-daily treatment, and dosing in animal models can be used according to 
approximate human exposure. 
 
2.5.4 Schedule optimization of radiotherapy and ZD6474 
Schedule optimization of radiotherapy and antiangiogenic combination therapy may 
differ among a variety of tumor types. Williams et al. (Williams et al., 2004) assessed the 
in vivo effect of chronically administered ZD6474 (25 or 50 mg/kg/d), with or without 
radiotherapy (three fractions of 2 Gy on days 1–3) in a Calu-6 human lung cancer 
xenograft model. Two schedules were examined: (1) ZD6474 dosing initiated 2 h before 
the first radiation dose (concurrent schedule), and (2) ZD6474 dosing initiated 30 min 
after the last radiation dose (sequential schedule). The growth delay induced using the 
concurrent schedule was significantly greater than that induced by either ZD6474 or 
radiotherapy alone. However, when administered sequentially, the tumor growth delay 
was markedly enhanced. Recent studies by Gustafson et al. (Gustafson et al., 2004) of a 
head-and-neck squamous cell carcinoma xenograft model indicated that concurrent 
administration of ZD6474 and radiotherapy significantly delayed tumor growth and was 
superior to single modalities or sequential combination therapies. The antitumor effects 
of ZD6474 doses was also examined in a human colorectal cancer xenograft model 
(HT29), either alone or combined with radiotherapy (Siemann et al., 2004). Three 
different schedules of combination therapy were assessed: ZD6474 before radiotherapy, 
concurrent administration, and ZD6474 after radiotherapy. In that model, irrespective of 
sequencing, concurrent therapy resulted in a significantly greater growth delay than either 
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radiotherapy or ZD6474 treatment alone. The in vivo effects of combination therapy 
correlated with a reduction in VEGF expression.  
The rationale for the development of VEGF signaling inhibitors in combination with 
radiotherapy was originally based on the observation that VEGF could enhance 
endothelial cell survival (Gorski et al., 1999). Consequently, a number of studies have 
shown that VEGF-targeting approaches can induce endothelial cell radiosensitization in 
vitro (Gorski et al., 1999; Geng et al., 2001). Some studies have suggested that 
VEGFR-blockade can lead to a transient normalization of the vasculature, leading to a 
window of opportunity when perfusion, oxygenation, and consequently, radiation 
response may be improved (Tong et al., 2004; Winkler et al., 2004). It is proposed that 
optimal treatment scheduling corresponds to administration of irradiation during a period 
of vascular normalization that is induced by the anti-VEGFR-2 therapy (Jain, 2001). 
Because tumors induce high levels of VEGF and angiogenesis, the antiangiogenic drug or 
VEGFR-blockade administration serves to balance this pathologic angiogenesis. 
Therefore, it is suggested that this period of normalization represents a balance between 
proangiogenic and antiangiogenic factors that transiently improves tumor blood flow and 
oxygenation (Jain, 2005). Because hypoxia is known to decrease the efficacy of 
radiotherapy (Wachsberger et al., 2003), giving radiation during this normalization 
window could serve to enhance treatment before the tumor vessels are irreversibly 
damaged and tumor blood flow is diminished by irradiation. 
Overall, ZD6474, is a potent (half inhibit concentration, IC50, 40 nmol/L), orally 
active, low molecular weight inhibitor of VEGF, and has additional activity versus the 
EGFR tyrosine kinase (IC50, 500nmol/L) (Ciardiello et al; 2003). Chronic oral dosing of 
mice bearing human tumor xenografts with ZD6474 has been previously shown to induce 
a dose-dependent inhibition of tumor growth (Wedge et al., 2002). And some results have 
suggested that ZD6474 may be a successful agent combined with clinical radiotherapy in 
a variety of tumor types (Gustafson et al., 2008; Bianco et al., 2006; Damiano et al., 
2005). However the optimal scheduling of treatments when ZD6474 combined with 
radiotherapy will continue to be an important issue to be assessed. 
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2.6 Aim of the project 
ZD6474 is a newly developed anti-angiogenic agent that selectively targets two key 
pathways in tumor growth by inhibiting VEGFR and EGFR tyrosine kinase activity. 
While VEGFR signaling promotes an array of responses in the endothelium including 
endothelial cell proliferation and angiogenesis, EGFR signaling regulates principal 
cellular processes including proliferation, differentiation and apoptosis after cytotoxic 
stress. The purpose of the present study was to evaluate the antitumor efficacy of a 
combination of ZD6474 and radiotherapy in a human tumour xenograft model (Fadu, 
squamous cell carcinoma) and to investigate whether the effects of the treatments are 
related to changes in tumor perfusion and tumor proliferation and apoptosis. 
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3. Materials and Methods 
3.1 Tumor cell line 
Fadu tumor cells (squamous cell carcinoma of head and neck) were maintained as a 
monolayer in RPMI 1640 supplemented with 10% fetal bovine serum and 0.01% (v/v) 
L-glutamine and penicillin/streptomycin. All cells were maintained at 37°C in a 5% CO2 
incubator. 
 
3.2 Animal cares 
Female athymic nude mice (nu/nu, body weight, 20–25 g, 8–12 weeks of age), were 
purchased from Charles River Laboratories, Inc (Wilmington, MA). All mice were provided 
sterilized food and water and housed in a barrier facility with 12-h light and dark cycles 
and in laminar flow hoods with constant temperature and humidity for the whole course 
of the experiments and supplied with standard laboratory diet and water (Sano et al., 2007; 
Brazelle et al., 2006). The mice were allowed to acclimatize from shipping for 1 week 
before use. The care and treatment of all experimental mice was in accordance with 
institutional guidelines. 
 
3.3 Tumors xenografts 
2 days before the tumor xenografts were established, all the mice were whole-body 
irradiated with 4 Gy (6-MV linear accelerator, MDX, Siemens) to suppress the 
immunoreactions. Fadu cells were prepared at a concentration of 2 x 107cells/mL in a 1:1 
mix of serum-free RPMI1640, and were intradermal injected to the right hind leg of the 
mice with. 
 
3.4 Drug and/or radiation treatment schedules  
After 7 days, when established tumor size reached at about 6 mm in diameter, all the 
mice bearing Fadu tumors were randomly assigned to 4 study groups (n = 6–8 mice per 
group): 
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Control group:  
No treatment was given to the mice. 
ZD6474 alone group:  
ZD6474 was administered daily by oral gavage (50 mg/kg, at volume of 0.1 mL/10g 
of body weight) for a period of 4 weeks (Monday to Friday). 
Radiotherapy alone group: 
Tumor irradiations were performed using a 6-MV linear accelerator, and localized 
radiotherapy was administered on anesthetized mice confined in plastic jigs. The tumor 
bearing limb was extended through an opening of the jig, allowing local tumor irradiation. 
The total dose was 10 Gy (5 × 2 Gy, days 1–5). 
Combination treatment with ZD6474 and radiotherapy group: 
ZD6474 (50 mg/kg, by mouth, once daily) was given 2 hours before each dose of 
radiation (5 × 2 Gy, days 1–5). 
 
3.4 Tumor response assessment 
Tumor size was measured using callipers every two days from the time of initial 
treatment to the time tumor size reached 2.5 cm3. Tumor volumes (V) were determined 
by the two axes of the tumor (L, longest axis; W, shortest axis). Volume was calculated 
according to the following formula as:  
Tumor volume (cm3) = (L x W2) x π/6, where L and W are the shortest and the 
longest diameter (Hessel et al., 2004). 
The tumor size and days of tumor growth were recorded until tumor volume reached 
2.5 cm3. 
 
3.5 Immunohistochemical evaluation of the xenograft tumors 
Mice were implanted with Fadu cells, after 6 to 8 days, mice were divided into 4 
groups to receive different treatment as described above in the tumor volume studies. In 
the drug treatment group, the mice were treated with 50 mg/kg ZD6474 p.o. daily for 5 
days. Mice in the radiation treatment group were treated with 2 Gy daily fractions for 5 
days, given by use of a 6 MV linear accelerator as described above in the tumor volume 
studies, and in combination treatment group, drug was delivered 2h before daily 
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irradiation. One week after 5 days treatments, mice were killed and the xenograft tumors 
sections were separated, tumor tissues from four mice from each treatment group were 
fixed and embedded in paraffin, then sectioned in 5 µm.  
 
3.5.1 Evaluation of vessel density 
To evaluate angiogenesis and vessel density, the antibody against CD34 was used. 
CD34 is a myeloid progenitor cell antigen and also present in endothelial cells, it can be 
detectable in all types of endothelium (Folkman, 1995). The monoclonal antibody against 
CD34 reacts with endothelium of arteries and venules, and has been found to stain more 
intensely capillary endothelium (Fina et al., 1990). It has been used for the diagnosis of 
vascular tumors and detection of small vessel proliferation representing angiogenesis 
(Schaerer et al., 2000). 
To evaluate vessel density, an immunofluorescence technique and antibody against 
CD34 were utilized. Briefly After deparaffinization and rehydration using the following 
series of washes: two xylene washes (10 min each), followed by 100% ethanol, 96% 
ethanol, 90% ethanol, 80% ethanol, 70% ethanol rinses (2 min each), the sections were 
washed by H2O for 1 min. Antigen retrieval was performed by heating the sections for 60 
min with citrate buffer (DAKO Retrieval puffer, #S-2031, Glostrup, Denmark pH 6.0) at 
96°C for unmasking the antigenic sites. After washing the sections with PBS for 5 min on 
a shaker, samples were blocked with normal goat serum (cat. #642921 ICN, Irvine, CA, 
USA) at room temperature for 60 min in order to diminish non-specific binding sites. 
Afterwards the tissue sections were incubated with primary monoclonal antibody of rat 
anti-mouse CD34 (United States Biological Inc, Massachusetts, Cat #C2386-02C) at a 
dilution of 1:100 in PBS in the humidified chamber overnight at 4°C, then the sections 
were incubated with biotinylated Alexa Fluor 488-conjugated goat anti-rat secondary 
antibody IgG (Invitrogen, Karlsruhe, Germany, cat. #A11006) diluted 1:200 in PBS in a 
humidified chamber for 60 min at room temperature in dark. Finally the sections were 
counterstained with DAPI and mounted in Entellan (Merck, Darmstadt, Germany) at 4°C 
overnight protected in the dark. Between each step the sections were washed by PBS 
(3x10 min). 
Sections were examined on a Nikon fluorescent microscope. Blood vessel density 
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was quantified that each slide was scanned at low power (x10-100) and the area with the 
higher number of new vessels was identified (hotspot). This region was then scanned at 
x600 microscope magnification. Three fields (0.15 mm2 per microscopic field) were 
analyzed and, for each of them, the number of stained blood vessels was counted. For 
individual tumors, microvessel count was scored by averaging the three field counts 
(Sano et al., 2007). 
 
3.5.2 Evaluation of tumor proliferation and apoptosis 
To evaluate the prolifreration of tumor tissue, the proliferation antigen Ki67 was used 
to assess the proliferating rate of tumor in different treatment group. The proliferation 
antigen Ki67 is detectable in cells at all phases of the cell cycle except G0 (Gerdes et al., 
1983), and the Ki67 labeling index (the percentage of cells with Ki67 positive nuclear 
immunostaining) is a measure of tumor proliferation (Lehr et al., 1999; Thor et al., 1999). 
Other studies (Chang et al., 2000; Archer et al., 2003) have suggested that a high Ki67 
labeling index can be as a predictor of responsiveness to adjuvant therapy. To evaluate 
the prolifreration of tumor tissue, the antibody against Capase-3 was used. Capases are 
family of cytosolic aspartate specific cysteine proteases involved in the initiation and 
execution of apoptosis. Capase-3 is a member of apoptosis execution group of capases, it 
can be activated when cells undergo apoptosis (Nicholson et al., 1995). 
The immunofluorescence technique and antibody against Ki67 and Capase-3 were 
utilized. After deparaffinization and rehydration using the following series of washes: 
two xylene washes (10 min each), followed by 100% ethanol, 96% ethanol, 90% ethanol, 
80% ethanol, 70% ethanol rinses (2 min each), the sections were washed by H2O for 
1 min, antigen retrieval was performed by heating the sections for 60 min with citrate 
buffer (DAKO Retrieval puffer, #S-2031, Glostrup, Denmark pH 6.0) at 96°C for 
unmasking the antigenic sites. After washing the sections with PBS for 5 min on a shaker, 
samples were blocked with normal goat serum (cat. #642921 ICN, Irvine, CA, USA) at 
room temperature for 60 min in order to diminish non-specific binding sites. Afterwards 
the tissue sections were incubated with primary monoclonal antibody of rat anti-mouse 
Ki67 (at a dilution of 1:200, Dako Gmbh, Hamburg, Germany) or rabbit anti-Capase3 
(1:100, Epitomic Inc, Burlingam CA, USA) in the humidified chamber overnight at 4°C, 
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then the sections were incubated with biotinylated Alexa Fluor 488-conjugated goat 
anti-rat (Invitrogen, Karlsruhe, Germany, cat. #A11006) or goat anti-rabbit (Invitrogen, 
Karlsruhe, Germany, cat. #A11008) secondary antibody IgG diluted 1:200 in PBS in a 
humidified chamber for 60 min at room temperature in dark. Finally the sections were 
counterstained with DAPI and mounted in Entellan (Merck, Darmstadt, Germany) at 4°C 
overnight protected in the dark. Between each step the sections were washed by PBS 
(3x10 min). 
Sections were examined on a Nikon fluorescent microscope. To determine the 
percentage of positive cells with Ki67, at least 500-1000 tumor cells per slide were 
counted, the number of Ki67-positive cell was scored and the positive rate was counted. 
To quantify the analysis of apoptosis, the number of apoptotic cells or Capase-3 stained 
positive cells was counted in 5 fields (0.15 mm2 per microscopic field) under x600 
microscope magnification in each tumor section per treatment group; results were 
expressed as positive cells per field. 
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4. Results 
4.1 Assessment of tumor growth delay 
4.1.1 Inhibition of xenograft growth in nude mice 
We evaluated the effects induced by radiotherapy and ZD6474 treatment in an in vivo 
model. 1 week after tumor cell injection, tumor size reached about 6 mm in diameter; all 
the mice were treated differently in 4 groups according to the plan. When tumor volume 
reached 2.5 cm3, mice were sacrificed. The progress of tumor growth was recorded every 
other day. The tumors in the control group (untreated mice) needed about 28 days to 
reach a volume of 2.5 cm3. At the same time point, the tumor growth in mice treated with 
either radiotherapy alone or ZD6474 alone or combination treatment with ZD6474 and 
radiotherapy was markedly inhibited. Respectively, it needed about 40 days, 45 days and 
49 days for the tumor volume to reach 2.5 cm3. So the inhibition effect in combination 
treatment with ZD6474 and radiotherapy group was better than ZD6474 alone group, and 
better than radiotherapy alone group (Fig. 5; Table 1). 
 
4.1.2 ZD6474-mediated tumor growth inhibition  
In the present study, ZD6474 has shown to produce a significant inhibition of Fadu 
cell xenograft growth. Fadu cell is an aggressive tumor cell line with high proliferating 
rate, the time taken for control tumors to achieve 2.5 cm3 was about 28 days. However, at 
the same time the mean tumor volume in ZD6474 alone group was 1.0 cm3, far smaller 
than in control group, it was about 45 days for ZD6474 alone group to reach end point, 
the difference between ZD6474 alone group and control group is obvious. (Fig. 5; 
Table 1). Thus ZD6474 treatment induced a highly significant inhibition of tumor growth 
in the present study. 
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4.1.3 ZD6474 combined with radiotherapy produces an enhancement of 
antitumor activity 
The potential of ZD6474 to enhance the outcome of radiotherapy in Fadu cell 
xenografts was investigated in a concurrent schedule whereby 50 mg/kg ZD6474 was 
given 2 hours before radiation (2 Gy per day) every day for a period of 5 days. When 
tumor in radiotherapy alone group reached 2.5 cm3, the mean tumor volume was 0.7 cm3 
in ZD6474 combined with radiotherapy treatment group. The time to achieve the end 
point in the combined treatment group was about 49 days, obviously greater than that 
seen in tumors treated only with radiotherapy (40 days) or only with ZD6474 (45 days), 
that there was an apparent difference between radiotherapy and ZD6474 combined with 
radiotherapy treatment (Fig. 5; Table 1). 
 
Table.1: Chronic daily dosing of ZD6474 (50 mg/kg) enhances the response of Fadu 
xenografts to fractionated radiotherapy 
 
Treatment Mean days (1)  when Tumor volume (2.5cm3)
Mean days (2) 
Growth delay  
   Control 27.5 ± 1.2 NA 
Radiotherapy alone (RT) 40.0 ± 0.7 12.5 ± 0.7 
ZD6474 alone 45.2 ± 3.0 17.7 ± 3.0 
ZD6474+RT 48.9 ± 2.8 21.4 ± 2.8 
 
NOTE: 
(1) Tumors were treated daily in different groups until the tumor volume reached 
2.5 cm3 was. The days of tumor growth were recorded and compared. 
(2) Tumor Growth delay is a comparison of the days of tumor growth between different 
treatment group and control (days of TV 2.5 cm3 treated – days of TV 2.5 cm3 
control).  
Values shown are the mean ± SE.  
Abbreviations: NA, not applicable; TV, tumor volume 
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Fig. 5: Inhibition of in-vivo growth of Fadu tumors in nude mice treated with 
radiotherapy alone (RT: 5 x 2 Gy, days 1-5), ZD6474 alone (ZD6474: 50 mg/kg/d) and 
their combination (ZD6474 + RT) compared with control without treatment. Data points 
represent mean values obtained from six to eight animals. Error bars represent the SE of 
6-8 experiments. 
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4.2 ZD6474 with radiotherapy reduces vascular density in Fadu 
xenograft tumors 
To determine the effects of ZD6474, radiation, and combination treatment with 
ZD6474 and radiotherapy on endothelial cells in vivo, histological assessments of vessel 
density were done on tumors excised one week after 5 days of continuous treatment. To 
relate changes in the endothelial compartment to the pathology of the tumor as a whole, 
the extent of tumor proliferation and apoptosis were also assessed. An antibody for CD34 
was used to stain for blood vessels. A representative image is shown in Fig. 6 A. The 
number of vessels per microscopic field was determined for each treatment group. 
Sections were examined on a Nikon fluorescent microscope. Blood vessel density was 
quantified that each slide was scanned at low power (x10-100) at first and the area with 
the higher number of new vessels was identified (hotspot). This region was then scanned 
at x600 microscope magnification. Three fields (0.15 mm2 per microscopic field) were 
analyzed and, for each of them, the number of stained blood vessels was counted. For 
individual tumors, microvessel count was scored by averaging the three field counts 
(Sano et al., 2007). Our study has shown control tumors had an average of 30.9 ± 1.4 
vessels per microscopic field, radiotherapy alone had 21.6 ± 1.7 vessels, ZD6474 alone 
had 17.5 ± 2.3 and combination treatment with ZD6474 and radiotherapy had 12.5 ± 0.6, 
the number of vessels was lowest in the combination treatment sections. Both ZD6474 
(50 mg/kg) daily for 5 days and radiotherapy alone (5 × 2 Gy) reduced vessel density in 
Fadu tumors compared with control. However, it was when both agents were applied 
concomitantly that this change achieved significantly enhanced compared with 
radiotherapy alone (Fig. 6 A and B). 
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Fig. 6 A: ZD6474 in combination with irradiation decreases vascular density in Fadu 
xenograft tumors. Histological sections were obtained from the tumors of the mice in 
each treatment group after one week treatment with ZD6474 and with or without 
irradiation; total vessel density was assessed using immunostaining for CD34 as a marker 
of endothelial cells. Images were shown at ×600 magnification. 
 
 
Fig. 6 B: Quantification analysis of blood vessel in tumor. Average blood vessel density 
of each treatment group was determined by counting the number of blood vessels at an 
area of 0.15 mm2 per microscopic field. Data presented are average values. Error bars 
represent the SE of 3-4 experiments. 
ZD6474 alone ZD6474+RT 
Control RT alone 
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4.3 ZD6474 with radiotherapy reduces proliferation in Fadu xenograft 
tumors 
To determine whether the tumor growth delay from the combined therapy results 
from decreased tumor proliferation, immunofluorescence technique and antibody against 
Ki67 were utilized to evaluate tumor proliferation. Ki67 staining was done using tissue 
sections from Fadu tumors in all treatment groups. Sections were examined on a Nikon 
fluorescent microscope and the proliferating rate was then determined in each treatment 
group. To determine the percentage of positive cells with Ki67, at least 500 - 1000 cancer 
cells per slide were counted and the number of positive cell were scored. Results were 
shown in Fig. 7 A and B. 
Our results have shown tumor in mice of control group had a very high proliferating 
rate with an average positive rate of 50% ± 1%; radiotherapy alone had an average 
positive rate of 21% ± 2%; ZD6474 alone had an average positive rate of 15% ± 1%, and 
combination treatment with ZD6474 and radiotherapy had an average positive rate of 9% 
± 1%. Compared with control, ZD6474 alone or radiotherapy alone inhibited tumor 
proliferation; the difference was obvious. However, when ZD6474 was combined 
radiotherapy, the positive rate of Ki67 was lowest in all treatment sections, and compared 
with ZD6474 alone or radiotherapy alone, the inhibited effect was increased. The 
difference between ZD6474 combined with radiotherapy and ZD6474 or radiotherapy 
alone was significantly increased. 
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Fig. 7 A: ZD6474 in combination with irradiation reduces Ki67 expression in Fadu 
xenograft tumors. Histological sections were obtained from the tumors of the mice in 
each treatment group after one week treatment with ZD6474 and with or without 
irradiation; standard Ki67 stainings were done. Immunofluorescence staining was shown 
at × 600 magnification in 4 groups. 
 
 
Fig. 7 B: Quantification of proliferative rate in tumor. Average proliferative rate of each 
treatment group was determined by counting Ki67 positive cells in 500-1000 tumor cell 
under microscopic field at ×600 magnifications. Data presented are average values. Error 
bars represent the SE of 3-4 experiments. 
ZD6474 alone ZD6474+RT 
Control RT alone 
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4.4 ZD6474 with radiotherapy increases apoptosis in Fadu xenograft 
tumors 
To determine whether the tumor growth delay from the combined therapy results 
from increased tumor apoptosis, Immunofluorescence technique and antibody against 
Capase-3 were utilized to evaluate tumor apoptosis. Capase-3 staining was done using 
tissue sections from Fadu tumors in all treatment groups. Sections were examined on an 
Nikon fluorescent microscope and the apoptosis index was then determined in each 
treatment group. To quantificate analysis of apoptosis in tumor, 5 fields (0.15 mm2 per 
microscopic field) were selected in each tumor section per treatment group under x600 
microscope magnification, cells with positive expression of Capase-3 were counted, and 
results were expressed as positive cells per field. Results were shown in Fig. 8 A and B. 
Our results have shown that tumors in the control group had a very low number of 
apoptotic cells per microscopic field (3.7 ± 0.3). The tumors in the radiotherapy alone 
group had an average number of 5.8 ± 0.3 and in the ZD6474 alone group had an average 
number of 5.2 ± 0.3 apoptotic cells per microscopic field. Combination treatment with 
ZD6474 and radiotherapy lead to a significantly higher number of apoptotic cells (11.5 ± 
0.5) per microscopic field.  
Compared with control, ZD6474 alone or radiotherapy alone increase apoptosis in 
tumor; the difference was obvious; however, when ZD6474 was combined radiotherapy, 
the difference was increased further. Compared with ZD6474 alone or radiotherapy alone, 
ZD6474 combined with radiotherapy enhanced the apoptosis in tumor. The difference 
between ZD6474 combined with radiotherapy and ZD6474 or radiotherapy alone was 
significantly increased. 
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Fig. 8 A: ZD6474 in combination with irradiation increases Capase-3 expression in Fadu 
xenograft tumors. Histological sections were obtained from the tumors of the mice in 
each treatment group after one week treatment with ZD6474 and with or without 
irradiation; standard Capase-3 stainings were done. Immunofluorescence staining were 
shown at ×600 magnification in 4 groups. 
 
 
Fig. 8 B: Quantification analysis of apoptosis index in tumor. Average apoptosis index of 
each treatment group was determined by counting the number of Capase-3 positive cell at 
an area of 0.15 mm2 per microscopic field. Data presented are average values. Error bars 
represent the SE of 3-4 experiments. 
ZD6474 alone ZD6474+RT 
Control RT alone 
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5. Discussion 
5.1 ZD6474 inhibits VEGF signaling, angiogenesis, and tumor growth 
following oral administration 
Tumor growth requires access to oxygen and nutrients carried by blood vessels. 
Tumor cells meet this nutritional need by influencing the surrounding host stroma to 
induce formation of new blood vessels, which subsequently grow within the tumor 
(angiogenesis). Angiogenesis plays a central role in the exponential growth of primary 
tumors and metastases. Strategies directed toward inhibition of tumor angiogenesis hold 
promise in cancer therapeutics with the first antiangiogenic agent achieving approval 
from Food and Drug Administration in 2004 (Tortora et al., 2004; Kerbel et al., 2004). 
Activated vascular endothelium represents an attractive target because of its rich 
accessibility to drugs, genetic stability (less likely to develop resistance), tissue 
homogeneity, and presence of a proliferating state primarily within tumor tissue.  
Many factors have been implicated in promoting angiogenesis; VEGF plays a key 
role in tumor angiogenesis including induction of endothelial cell proliferation, migration, 
survival and capillary tube formation (Kanno et al., 2000). Enhanced production of 
VEGF is generally correlated with increased neovascularization within tumors (Kerbel et 
al., 2000; Fontanini et al., 1997). Different mechanisms, notably hypoxia can increase 
VEGF expression in cancer cells (Kerbel et al., 2000; Ferrara et al., 1992). VEGF binds 
to two distinct receptors on endothelial cells, i.e. flt-1 (VEGFR-1) and flk/KDR receptor 
(VEGFR2) (Ferrara et al., 1992). VEGFR-2 is considered to be the dominant signaling 
receptor for endothelial cell permeability, proliferation, and differentiation (Ferrara et al., 
2003). VEGF and its receptors are good targets for cancer therapy because VEGF 
receptors are highly specific for VEGF and are expressed in increased numbers primarily 
during periods of tumor growth (Cherrington et al., 2000). The integral role of the 
VEGF/VEGFR2 pathway in tumor angiogenesis is supported by numerous studies, 
including those that show inhibition of tumor growth in nude mice by anti-VEGF 
antibodies (Willett et al., 2004), anti-Flk1 antibodies (Kozin et al., 2001), inhibitors of 
VEGFR2 tyrosine kinase (Drevs et al., 2000; Abdollahi et al., 2003), anti-VEGF 
antisense RNA (Saleh et al., 1996; Ellis et al.,1998 ), and VEGF toxin (Ramakrishnan et 
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al., 1996). 
ZD6474 is a potent, low molecular weight inhibitor of VEGFR2 tyrosine kinase 
activity (Hennequin et al., 2002), which significantly inhibits tumor growth in a broad 
range of established human cancer xenografts in nude mice and is currently undergoing 
clinical evaluation (Miller et al., 2005; Heymach et al., 2005). ZD6474 also has 
additional activity against EGFR tyrosine kinase (Ciardiello et al., 2003; Ryan et al., 
2005). ZD6474 has potent antitumor activity by a direct antiangiogenic mechanism via 
inhibition of VEGFR2 signaling in endothelial cells, and can also directly inhibit cancer 
cell growth by interfering with the EGFR autocrine pathway which is central to cancer 
growth and progression. Overexpression of EGFR and/or its ligands, transforming growth 
factor TGF-α and EGF has been reported in many human tumor types (Ciardiello et al., 
2001). Furthermore, ZD6474 could block neoangiogenesis more efficiently than more 
selective anti-VEGFR agents, because in addition to a direct inhibitory effect on 
VEGFR2 signaling, it also has an indirect effect on angiogenesis via blockade of EGFR 
induced paracrine production of angiogenic growth factors (Wedge et al., 2002; 
Ciardiello et al., 2003).  
In this study, ZD6474 proved to be an effective agent for suppressing growth of Fadu 
cells in vivo. Chronic once-daily oral administration of ZD6474 (50 mg/kg/day) produced 
an obvious inhibition of tumor growth in Fadu tumor xenograft models. To evaluate 
vessel density in vivo, histological analysis of immunohistochemical staining was utilized. 
Vessels were detected with an anti-CD34 antibody. After treatment with ZD6474, the 
number of CD34-positive endothelial cells decreased and the vessel number was 
significantly lower in the tumors treated with ZD6474 alone compared with control. To 
evaluate proliferating rate and apoptotic events in vivo, the marker of Ki67 and Capase-3 
were utilized. After treatment with ZD6474, the number of Ki67-positive tumor cells 
decreased and the number of Capase-3 positive tumor cells was significantly higher in the 
tumors treated with ZD6474 than that in the control. These data are compatible with 
inhibition of VEGF signaling because a significant reduction in tumor neovascularization 
and VEGF-induced vascular permeability could be expected to result in greater tumor 
ischemia and the induction of tumor cell necrosis. 
In conclusion, based on the present results, we show that in vivo ZD6474 was a 
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highly active antitumor agent by inhibition of VEGF-dependent angiogenesis, 
proliferation and induction of tumor cell apoptosis. These results suggest that ZD6474 
may have dual antitumor effects by i) inhibiting VEGF dependent tumor angiogenesis 
and VEGF-dependent endothelial cell survival, and ii) inhibiting tumor cell proliferation 
and promoting tumor cell apoptosis. ZD6474 has the potential to inhibit two key 
pathways in tumor growth via inhibition of VEGF-dependent tumor angiogenesis and via 
inhibition of EGFR-dependent tumor cell proliferation. In further, the efficacy of ZD6474 
combined with radiotherapy will be evaluated. 
 
5.2 ZD6474 increases the tumor response to radiotherapy 
 
5.2.1 ZD6474 produces an enhancement of radiotherapy through 
antiangiogenesis 
Although antiangiogenic agents have been shown to reduce the growth rate of tumors, 
treatment with these agents alone is unlikely to be curative (Siemann et al., 2004). 
However, combining antiangiogenic agents with other modalities may lead to an overall 
increase in antitumor efficacy. When considering treatment options for combination 
studies, radiation therapy appears to be a good candidate given its extensive use and 
application in a wide variety of tumor types and clinical settings (DeVita et al., 1997).  
Radiation represents a central modality of treatment for many human cancers. 
Approximately one-half of all cancer patients receive radiation at some point during the 
course of their disease. The effectiveness of radiation is often limited by normal tissue 
tolerance or by tumor cell resistance to therapy. Molecular targeting of the tumor 
vasculature may influence the efficacy of radiotherapy in achieving locoregional tumor 
control (Gong et al., 2003; Fenton et al., 2004; Raben et al., 2004). Indeed, approaches 
using angiostatin (Mauceri et al. 1998), endostatin (Hanna et al., 2000), vascular 
microtubule formation inhibition (Siemann et al., 2002), and anti-VEGF treatment 
(Gorski et al., 1999; Lee et al., 2000) have shown enhanced antitumor effect of radiation 
in several preclinical studies with human tumor xenografts. With specific regard to 
VEGFR2, a report by Kozin et al. (Kozin et al., 2001) demonstrates that VEGFR2 
blockade by mAb DC101 reduces the dose of radiation required to control 50% of tumors 
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in two human xenograft model systems. Studies using an orally available inhibitor of 
VEGFR2 tyrosine kinase activity (ZD6474) also demonstrate antitumor activity (Wedge 
et al., 2002), and preliminary data in lung and head-and-neck tumor models suggest 
favorable interaction of ZD6474 with radiation (Shibuya et al., 2007; Hoang et al., 2006; 
Gustafaon et al., 2004). 
In the present study, we examined in vivo antitumor and antiangiogenic effects of 
VEGFR2 blockade by ZD6474, we have confirmed chronic once-daily oral 
administration of ZD6474 (50 mg/kg/day) produced an inhibition of tumor growth in 
Fadu tumor xenograft models. The growth-inhibitory effect of ZD6474 (VEGFR2 
blockade) on tumor xenografts seems to reflect antiangiogenic influence as revealed 
through an in vivo angiogenesis assay. We further investigated the effect of combined 
treatment with radiotherapy and ZD6474 on tumor xenograft response and angiogenesis. 
To explore the clinical viability of combining these two treatment modalities, we 
established a Fadu cell tumor xenograft model in nude mice. Mice were placed into four 
treatment groups: control, ZD6474 alone, radiotherapy alone, or ZD6474 combined with 
radiotherapy. To maximize clinical applicability, we chose to use five fractions dose (2 
Gy per day) irradiation on our tumor model. We found that chronic administration of 
ZD6474 caused a reduction of tumor growth, consistent with previous studies (Wedge et 
al., 2002). And when combined with fractionated radiotherapy, a significant increase in 
tumor growth delay was observed compared with either radiotherapy or ZD6474 alone. 
When tumor size reached 2.5 cm3, Mice in the control group needed about 28 days, 4 
weeks after tumor implantation. Respectively, it needed about 49 days, 45 days, 40 days 
for mice in combination treatment with ZD6474 and radiotherapy, ZD6474 alone, 
radiotherapy alone group. The growth delay was 17.7 ± 3.0 day for ZD6474 alone, 12.5 ± 
0.7 days for radiotherapy alone, and 21.4 ± 2.8 days for combination treatment (Fig. 5 
and table 1). The difference in tumor growth between treatment groups of ZD6474 
combined with radiotherapy and radiotherapy or ZD6474 alone is obvious, but compared 
with ZD6474 alone, the difference between combination treatment group and 
radiotherapy alone is significantly more obvious compared with ZD6474 alone (49 days 
versus 40 days versus 45 days for the tumor growth). In our project, the total dose of 
irradiation was only 10 Gy, but ZD6474 (50 mg/kg/day) was delivered for 4 weeks in 
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drug alone or combination treatment group. It can be the reason for the little difference 
between ZD6474 alone group and combination treatment group because of insufficient 
total dose of irradiation. In addition, because tumor regrowth after radiotherapy was 
slowed and the extent of tumor regression postradiotherapy was enhanced obvously in 
combination treatment group, it also can be explained as constantly excellent antitumor 
effect with the continuous application of ZD6474 after radiotherapy ended. 
To determine the effects of ZD6474 treatment on tumor neovascularization, 
proliferation and apoptosis in vivo, 4 mice per group were sacrificed one week after 5 
days treatment. Tumor tissues were then collected and analyzed, using antibodies against 
CD34; microvessel number was assessed in the most intense areas of neovascularization. 
And the marker of Ki67 and Capase-3 were utilized to evaluate proliferating rate and 
apoptotic events in vivo. Our results showed that tumor vascular density was significantly 
decreased by combination therapy with ZD6474 and radiotherapy (Fig. 6 A and B). This 
decrease in vascular density was observed 7 days after initiation of ZD6474 treatment. 
This abolition of tumor vasculature not only shows the value of ZD6474 in enhancing 
radiation-induced vascular damage but also underscores the previously discussed 
importance of optimal treatment scheduling when using anti-VEGFR2 agents. Consistent 
with the tumor growth delay, under the chosen treatment schedule, we observed 
decreased proliferation through Ki67 staining of histologic sections from the Fadu cell 
xenograft tumors. There was a notable decrease in Ki67 staining in the tumor sections 
that received treatment of ZD6474 combined with radiotherapy, compared with control or 
either treatment alone (Fig. 7 A and B). Similarly, apoptosis was increased in the 
combination treatment group compared with controls (Fig. 8 A and B). These data 
suggest that ZD6474 increases tumor response to radiotherapy through inhibition of 
tumor angiogenesis, and the mechanism of tumor growth delay also included both 
decreased proliferation and increased apoptosis of tumor cells. 
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5.2.2 The possible radiosensitive mechanisms of antiangiogenesis from 
ZD6474 
ZD6474 treatment resulted in significant in vivo tumor growth retardation. This 
growth inhibition was significantly enhanced when ZD6474 was combined with 
fractionated dose radiotherapy. Regarding potential mechanisms whereby VEGFR2 
blockade and radiation induce cell death, ZD6474 is thought to exert antitumor effects 
through inhibition of angiogenesis and induction of endothelial cell apoptosis (Wedge et 
al., 2002). Our present studies are compatible with this conclusion. Although one might 
speculate that VEGFR2 blockade could reduce the efficacy of radiation by reducing 
tumor oxygenation due to diminished vascularization, our results suggest the converse. In 
other words, VEGFR2 blockade in our model system showed enhanced efficacy of 
radiation on tumor response. The positive interaction observed when ZD6474 is used as 
an adjuvant to radiotherapy supports an important role for VEGF-mediated signaling in 
the tumor response to radiotherapy in vivo. Several mechanisms have been postulated by 
which inhibitors of VEGF signaling could improve the therapeutic effects of radiation. 
These include a normalization of tumor vasculature (Winkler et al., 2004) and a direct 
enhancement of the radiosensitivity of tumor endothelial cells (Gorski et al., 1999). 
 
5.2.2.1 Vascular normalization and radiosensitization 
The study by Kozin et al. similarly reports that DC101, a VEGFR2 blockade, can 
potentiate radiation response among a series of human tumor xenografts (Kozin et al., 
2001). Furthermore, several recent studies (Gong et al., 2003; Winkle et al., 2004; Tong 
et al., 2004) suggest that VEGFR2 blockade may create a “normalization window”, a 
period during which radiation treatment can induce maximal tumor impact. This window 
is characterized by an increase in tumor oxygenation, which is known to enhance 
radiation response. Because there is a critical window during which the interaction 
between anti-VEGFR2 therapy and radiotherapy is maximized, it is proposed that optimal 
treatment scheduling corresponds to administration of radiation during a period of 
vascular normalization that is induced by the anti-VEGFR2 therapy (Jain, 2001). Because 
tumors induce high levels of angiogenesis, the antiangiogenic drug administration serves 
to balance this pathologic angiogenesis. Therefore, it is suggested that this period of 
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normalization represents a balance between proangiogenic and antiangiogenic factors that 
transiently improves tumor blood flow and oxygenation (Jain, 2005). Because hypoxia is 
known to decrease the efficacy of radiotherapy (Wachsberger et al., 2003), giving 
irradiation during this normalization window could serve to enhance treatment before the 
tumor vessels are irreversibly damaged and tumor blood flow is diminished by radiation. 
Alternatively, a crucial role for VEGF in tumor remodeling and growth postradiotherapy 
has been suggested from studies demonstrating a positive interaction between 
radiotherapy and VEGF-targeting when the agent is given as an adjuvant to radiation 
(Zips et al., 2003; Williams et al., 2004; Zips et al., 2005). These data have lead to the 
suggestion that preirradiated tumor vasculature is more sensitive to inhibition of VEGF 
signaling. In our study, ZD6474 (50 mg/kg, by mouth, once daily) was given 2 hours 
before each dose of radiation (5 × 2 Gy, days 1–5) in combination treatment schedule, it 
did have produced a greater control of tumor growth during the course of radiotherapy 
and supported above ideas. 
 
5.2.2.2 Endothelial radiosensitivity and radiosensitization 
However, Fenton et al. (Fenton et al., 2004) also provide evidence to suggest that 
VEGFR2 blockade can enhance radioresponse by specifically sensitizing endothelial 
cells (possibly via enhancement of endothelial cell apoptosis) despite the induction of 
hypoxia in the tumor. This concept of the endothelial cell as primary target governing 
ultimate radiation response has been recently postulated using a mouse intestinal model 
system (Paris et al., 2001). Damage to the endothelial cell compartment would thereby 
facilitate subsequent damage to tumor cells, counter to the prevailing hypothesis that 
radiation damage targets primarily the malignant cell (Garcia-Barros et al., 2003). It has 
also been speculated that antiangiogenic therapies may block the endothelial cell VEGF 
production induced by radiotherapy, thus inhibiting a survival advantage for tumor 
endothelium (Kermani et al., 2001) and resulting in impairment of tumor cell growth and 
survival in a more indirect manner. Blockage of VEGF, it is hypothesized, would lead to 
an increase in endothelial cell apoptosis and thus lead to greater tumor cell death than 
radiation alone. 
Our present results have presented combination of ZD6474 with radiotherapy induced 
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a notable decrease in tumor proliferation and increase of apoptosis compared with either 
treatment alone. If this observation is further generalized, increased endothelial 
radiosensitivity after VEGFR2 blockade might explain the potent interactive killing of 
tumor xenografts observed with the combination of ZD6474 and radiotherapy. Our 
improved understanding of the molecular interplay between radiation and these 
angiogenic factors should facilitate the design and testing of new clinical trial strategies. 
 
5.3 Conclusion 
In summary, the present studies indicate that VEGFR2-associated tyrosine kinase 
inhibition by the small molecule ZD6474 improves the response of Fadu tumor 
xenografts to fractionated radiotherapy through: 
(a) ZD6474 appears to target tumor cells and tumor vasculature by both indirect and 
direct mechanisms (inhibition of EGFR/VEGF pathways). 
(b) ZD6474 can decrease overall tumor resistance to radiation by targeting both tumor 
cells and tumor vasculature. 
(c) Tumor growth and angiogenesis are part of a codependent cycle. ZD6474 can break 
the cycle and prevent revascularization after radiation. 
(d) The enhancement effects observed with combined radiation and ZD6474 treatments 
on inhibition of tumor growth may arise from antiangiogenesis and the intrinsic 
radiosensitivities of endothelial cells. 
These results provide further impetus for future evaluation of the combination of 
ZD6474 with radiotherapy in the clinical setting. As antiangiogenic agents experience 
increased applications in cancer patients and their potential for use in conjunction with 
radiotherapy grows, uncovering the complex interactions involved between the two 
therapies will become even more vital to successful therapies for solid tumors. 
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Fig. 9: Possisble mechanisms for enhanced tumor response to radiation with ZD6474. 
ZD6474 may work synergistically with radiation through inhibition of neovascularization 
processes. ZD6474 may also improve radiosensitivity by directly and/or indirectly 
inhibiting protective cell survival signaling pathways in both endothelial and tumor cells, 
resulting in increased apoptosis in both the tumor cell compartment and the tumor 
stromal (i.e., endothelial cell) compartment.
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